Top

Published in:

01-04-2008 | Original Article

A novel murine model of allogeneic vaccination against prostate cancer

Authors: M.-C. Labarthe, P. Theocharous, N. Russell, S. Todryk, C. Bangma, P. Thraves, A. G. Dalgleish, M. A. Whelan

Published in: Cancer Immunology, Immunotherapy | Issue 4/2008

Abstract

Prostate cancer continues to be a major cause of death in men. Surgical and medical treatments of the disease have improved, but metastasic disease remains a significant clinical problem. Novel therapies such as whole cell vaccination offer the potential of treating disease by stimulating the immune system. To study the efficacy of a whole cell vaccine in prostate cancer two strains of mice were used: C57BL/6 (H-2Kb) and C3H/HeJ (H-2K^k) in combination with four different cell lines. Thus, a model was constructed of allogeneic and syngeneic vaccine, as well as a challenge tumour for each strain. Two novel cell lines were developed during this study. Firstly, the non tumourigeneic PMC-1 was derived from a normal mouse prostate and immortalized with HPV16. Secondly, the tumourigeneic PMC-1 C6ras1p1 was transformed with human ras gene which formed tumours in both SCID and C3H/HeJ mice. Protection, and the nature of the immune response to syngeneic and allogeneic vaccine, in males and females was examined in both strains. Vaccination with both syngeneic and allogeneic irradiated whole cell vaccines induced protection from syngeneic challenge in females. However, no protection was observed when allogeneic vaccine was given to male mice. This correlated with the immune response. Two types of cellular immune responses were generated in females. A NK-mediated response was observed in C57BL/6 mice, whilst C3H/HeJ mice developed a CTL response. Little or no cellular immune response was observed in males. The cytokine profile in C3H/HeJ females was a mixture of Th1 and Th2 whilst a mainly Th1 profile was observed in C57BL/6 mice. Male mice showed a diminished cytokine secretion compared to females which was further depressed after challenge. The difference in immunity was largely as expected, since tolerance to prostate antigens should not normally develop in female mice. However, this makes this model particularly relevant clinically since it directly mimics the human situation and thus may accelerate the development of whole cell vaccines for clinical use.

Abril E, Mendez RE, Garcia A et al (1996) Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon. Tissue Antigens 47:391–398PubMed

Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M (1992) Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52:5991–5996PubMed

Baars A, Claessen AM, van den Eertwegh AJ et al (2000) Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol 11:965–970PubMedCrossRef

Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC (1995) Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52:403–413PubMedCrossRef

Berard F, Blanco P, Davoust J et al (2000) Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192:1535–1544PubMedCrossRef

Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283–1288PubMedCrossRef

Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK (1993) Heat shock protein vaccines against cancer. J Immunother 14:352–356CrossRef

Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46:681–686PubMedCrossRef

Boon T, van der BP (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729PubMedCrossRef

10.

Bosland MC (1996) Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Prog Clin Biol Res 394:309–352PubMed

11.

Bostwick DG, Qian J (2001) Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 58:91–93PubMedCrossRef

12.

Bremers AJ, Andreola S, Leo E et al (2000) T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens. Int J Cancer 88:956–961PubMedCrossRef

13.

Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR (1998) Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 19:368–373PubMedCrossRef

14.

Chen PW, Ananthaswamy HN (1993) Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 151:244–255PubMed

15.

Chen X, Tao Q, Yu H, Zhang L, Cao X (2002) Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol Lett 84:81–87PubMedCrossRef

16.

Crawford ED, Blumenstein BA, Goodman PJ et al (1990) Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66:1039–1044PubMed

17.

Dillman RO, Barth NM, VanderMolen LA et al (2001) Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm 16:47–54PubMedCrossRef

18.

Dillman RO, Beutel LD, Cornforth AN, Nayak SK (2000) Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer. Cancer Biother Radiopharm 15:161–168PubMedCrossRef

19.

Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der BP (1999) A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 29:3329–3337PubMedCrossRef

20.

Eaton JD, Perry MJ, Nicholson S et al (2002) Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89:19–26PubMedCrossRef

21.

Haigh PI, Difronzo LA, Gammon G, Morton DL (1999) Vaccine therapy for patients with melanoma. Oncology (Huntingt) 13:1561–1574

22.

Hiipakka RA, Liao S (1998) Molecular mechanism of androgen action. Trends Endocrinol Metab 9:317–324

23.

Kayaga J, Souberbielle BE, Sheikh N et al (1999) Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther 6:1475–1481PubMedCrossRef

24.

Kircheis R, Kupcu Z, Wallner G, Rossler V, Schweighoffer T, Wagner E (2000) Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice. Cancer Gene Ther 7:870–878PubMedCrossRef

25.

Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. CA Cancer J Clin 48:6–29PubMed

26.

Lundak RL, Raidt DJ (1973) Cellular immune response against tumor cells. I. In vitro immunization of allogeneic and syngeneic mouse spleen cell suspensions against DBA mastocytoma cells. Cell Immunol 9:60–66PubMedCrossRef

27.

Peehl DM, Stamey TA (1986) Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol 22:82–90PubMedCrossRef

28.

Plaut M, Lichtenstein LM, Gillespie E, Henney CS (1973) Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol 111:389–394PubMed

29.

Rhim JS, Webber MM, Bello D et al (1994) Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci USA 91:11874–11878PubMedCrossRef

30.

Rosenberg SA, Kawakami Y, Robbins PF, Wang R (1996) Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 70:145–177PubMed

31.

Russo V, Tanzarella S, Dalerba P et al (2000) Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci USA 97:2185–2190PubMedCrossRef

32.

Santin AD, Hermonat PL, Ravaggi A et al (1998) The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. Int J Radiat Biol 73:699–704PubMedCrossRef

33.

Sarkar FH, Sakr WA, Li YW, Sreepathi P, Crissman JD (1993) Detection of human papillomavirus (HPV) DNA in human prostatic tissues by polymerase chain reaction (PCR). Prostate 22:171–180PubMedCrossRef

34.

Scheffer SR, Nave H, Korangy F et al (2003) Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 103:205–211PubMedCrossRef

35.

Sierra-Rivera E, Voorhees GJ, Freeman ML (1993) Gamma irradiation increases hsp-70 in Chinese hamster ovary cells. Radiat Res 135:40–45PubMedCrossRef

36.

Spandidos DA, Wilkie NM (1984) Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 310:469–475PubMedCrossRef

37.

Sumiya H, Masai M, Akimoto S, Yatani R, Shimazaki J (1990) Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. Eur J Cancer 26:786–789PubMedCrossRef

38.

Tamura Y, Peng P, Liu K, Daou M, Srivastava PK (1997) Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117–120PubMedCrossRef

39.

Tannock IF, de WR, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRef

40.

Thomas MC, Greten TF, Pardoll DM, Jaffee EM (1998) Enhanced tumor protection by granulocyte–macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 9:835–843PubMedCrossRef

41.

Truong LD, Rangdaeng S, Cagle P, Ro JY, Hawkins H, Font RL (1990) The diagnostic utility of desmin. A study of 584 cases and review of the literature. Am J Clin Pathol 93:305–314PubMed

Title: A novel murine model of allogeneic vaccination against prostate cancer
Authors: M.-C. Labarthe
P. Theocharous
N. Russell
S. Todryk
C. Bangma
P. Thraves
A. G. Dalgleish
M. A. Whelan
Publication date: 01-04-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0384-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis

Vγ9Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas

Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes

Progress in vaccination against cancer-7: report of the meeting in Stockholm, September 10–11, 2007

A simple but effective cancer vaccine consisting of an antigen and a cationic lipid

Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer